An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D

John H. Weis, Lynn William Enquist, John S. Salstrom, Roger J. Watson

Research output: Contribution to journalLetter

29 Citations (Scopus)

Abstract

Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) cause both persistent and latent infections, including recurrent cutaneous disease, lethal neonatal disease, central nervous system disease and other clinical syndromes1. Modified live vaccines or conventionally prepared subunit vaccines have generally been unsuccessful in the treatment of HSV-1 and HSV-2 infections from the standpoints of safety and efficacy2. It has been established that HSV-1 and HSV-2 infectivity may be neutralized in vitro with antisera directed specifically against each of the four major glycoproteins of the virus (gA/gB, gC, gD and gE)3,4 and antisera against glycoprotein gD, of either HSV-1 or HSV-2, are capable of neutralizing both HSV-1 and HSV-2 infectivity in vitro and in vivo5-8. We have previously reported on the identification, DNA sequence and expression at low level in Escherichia coli of the gD gene of HSV-1 strain Patton9. Here we describe construction of a hybrid gene encoding a chimaeric protein containing HSV-1 gD, bacteriophage λ Cro and E. coli β-galactosidase (gD-β-gal) protein, which is expressed at high level in E. coli. Moreover, the chimaeric protein elicits antibodies in rabbits that not only immunoprecipitate gD from cells infected with HSV-1 and HSV-2 but also neutralize HSV-1 and HSV-2 infectivity in vitro.

Original languageEnglish (US)
Pages (from-to)72-74
Number of pages3
JournalNature
Volume302
Issue number5903
DOIs
StatePublished - Dec 1 1983
Externally publishedYes

Fingerprint

Human Herpesvirus 1
Glycoproteins
Human Herpesvirus 2
Proteins
Escherichia coli
Infant, Newborn, Diseases
Immune Sera
Galactosidases
Subunit Vaccines
Central Nervous System Diseases
Infection
Skin Diseases
Bacteriophages
Genes

All Science Journal Classification (ASJC) codes

  • General

Cite this

Weis, John H. ; Enquist, Lynn William ; Salstrom, John S. ; Watson, Roger J. / An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D. In: Nature. 1983 ; Vol. 302, No. 5903. pp. 72-74.
@article{ce35361504194b6ba2efef0a86e70890,
title = "An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D",
abstract = "Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) cause both persistent and latent infections, including recurrent cutaneous disease, lethal neonatal disease, central nervous system disease and other clinical syndromes1. Modified live vaccines or conventionally prepared subunit vaccines have generally been unsuccessful in the treatment of HSV-1 and HSV-2 infections from the standpoints of safety and efficacy2. It has been established that HSV-1 and HSV-2 infectivity may be neutralized in vitro with antisera directed specifically against each of the four major glycoproteins of the virus (gA/gB, gC, gD and gE)3,4 and antisera against glycoprotein gD, of either HSV-1 or HSV-2, are capable of neutralizing both HSV-1 and HSV-2 infectivity in vitro and in vivo5-8. We have previously reported on the identification, DNA sequence and expression at low level in Escherichia coli of the gD gene of HSV-1 strain Patton9. Here we describe construction of a hybrid gene encoding a chimaeric protein containing HSV-1 gD, bacteriophage λ Cro and E. coli β-galactosidase (gD-β-gal) protein, which is expressed at high level in E. coli. Moreover, the chimaeric protein elicits antibodies in rabbits that not only immunoprecipitate gD from cells infected with HSV-1 and HSV-2 but also neutralize HSV-1 and HSV-2 infectivity in vitro.",
author = "Weis, {John H.} and Enquist, {Lynn William} and Salstrom, {John S.} and Watson, {Roger J.}",
year = "1983",
month = "12",
day = "1",
doi = "https://doi.org/10.1038/302072a0",
language = "English (US)",
volume = "302",
pages = "72--74",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "5903",

}

An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D. / Weis, John H.; Enquist, Lynn William; Salstrom, John S.; Watson, Roger J.

In: Nature, Vol. 302, No. 5903, 01.12.1983, p. 72-74.

Research output: Contribution to journalLetter

TY - JOUR

T1 - An immunologically active chimaeric protein containing herpes simplex virus type 1 glycoprotein D

AU - Weis, John H.

AU - Enquist, Lynn William

AU - Salstrom, John S.

AU - Watson, Roger J.

PY - 1983/12/1

Y1 - 1983/12/1

N2 - Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) cause both persistent and latent infections, including recurrent cutaneous disease, lethal neonatal disease, central nervous system disease and other clinical syndromes1. Modified live vaccines or conventionally prepared subunit vaccines have generally been unsuccessful in the treatment of HSV-1 and HSV-2 infections from the standpoints of safety and efficacy2. It has been established that HSV-1 and HSV-2 infectivity may be neutralized in vitro with antisera directed specifically against each of the four major glycoproteins of the virus (gA/gB, gC, gD and gE)3,4 and antisera against glycoprotein gD, of either HSV-1 or HSV-2, are capable of neutralizing both HSV-1 and HSV-2 infectivity in vitro and in vivo5-8. We have previously reported on the identification, DNA sequence and expression at low level in Escherichia coli of the gD gene of HSV-1 strain Patton9. Here we describe construction of a hybrid gene encoding a chimaeric protein containing HSV-1 gD, bacteriophage λ Cro and E. coli β-galactosidase (gD-β-gal) protein, which is expressed at high level in E. coli. Moreover, the chimaeric protein elicits antibodies in rabbits that not only immunoprecipitate gD from cells infected with HSV-1 and HSV-2 but also neutralize HSV-1 and HSV-2 infectivity in vitro.

AB - Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) cause both persistent and latent infections, including recurrent cutaneous disease, lethal neonatal disease, central nervous system disease and other clinical syndromes1. Modified live vaccines or conventionally prepared subunit vaccines have generally been unsuccessful in the treatment of HSV-1 and HSV-2 infections from the standpoints of safety and efficacy2. It has been established that HSV-1 and HSV-2 infectivity may be neutralized in vitro with antisera directed specifically against each of the four major glycoproteins of the virus (gA/gB, gC, gD and gE)3,4 and antisera against glycoprotein gD, of either HSV-1 or HSV-2, are capable of neutralizing both HSV-1 and HSV-2 infectivity in vitro and in vivo5-8. We have previously reported on the identification, DNA sequence and expression at low level in Escherichia coli of the gD gene of HSV-1 strain Patton9. Here we describe construction of a hybrid gene encoding a chimaeric protein containing HSV-1 gD, bacteriophage λ Cro and E. coli β-galactosidase (gD-β-gal) protein, which is expressed at high level in E. coli. Moreover, the chimaeric protein elicits antibodies in rabbits that not only immunoprecipitate gD from cells infected with HSV-1 and HSV-2 but also neutralize HSV-1 and HSV-2 infectivity in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0020676318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020676318&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/302072a0

DO - https://doi.org/10.1038/302072a0

M3 - Letter

VL - 302

SP - 72

EP - 74

JO - Nature

JF - Nature

SN - 0028-0836

IS - 5903

ER -